A Phase 1/2 interventional study of IMG-007 in Alopecia Areata (AA), sponsored by Inmagene LLC. Completed at 17 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-09.
Sponsored by Inmagene LLC · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies in Alopecia Areata with a site in United States — 21 open to participants now, 32 under way, 8 of them phase 3. Alopecia Areata · United States.
Among the 98 studies in Alopecia Areata with a site in United States, this one is the 54th largest by enrollment of the 84 interventional ones that give a count, is one of 9 that started in 2023, is one of 2 in phase 1/2, and was the 76th registered.
220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.
Browse Alopecia Areata studies →21 of the 98 studies in Alopecia Areata with a site in United States are open now. Recruiting first, the newest first:
AbbVie · Sites in United States, Australia, Japan and 1 more country
Ages 6–17
Pfizer · Sites in United States, Canada, China and 2 more countries
Ages 12+
Eli Lilly and Company · Sites in United States, Canada, China and 4 more countries
Ages 18–60
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 12+
Almirall, S.A. · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 48 · Phase 3 16 · Phase 4 8
First in 1997; this study’s year is marked. 9 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 29 is below the median of 50 across 171 interventional studies indexed under Alopecia Areata.
Median enrollment 46 across the 84 interventional studies, 2,300 across the 14 observational. Of the 60 that completed or were terminated, 42 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
52 of 98 have an industry lead sponsor. The 10 most frequent:
Inmagene LLC is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Inmagene LLC has 1 study filed under Alopecia Areata — fewer than ten, so there is no comparison to draw.
10 of the studies in Alopecia Areata with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07029711Phase 3PfizerA Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata | 2026-12-02 |
| NCT03898479Phase 3Sun Pharmaceutical Industries, Inc.Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | 2027-05 |
| NCT06826196Aldena TherapeuticsA Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata | 2026-11 |
| NCT07821216PfizerReal-World Effectiveness of Ritlecitinib in Alopecia Areata Patients in the US: A Retrospective Analysis Using EHR and Claims Data | 2026-11-20 |
| NCT06602232Dren BioA Study of DR-01 in Subjects With Alopecia Areata and Vitiligo | 2027-05 |
Add all 10 to your calendar (.ics) → With an account.
Among the 98 studies in Alopecia Areata with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to evaluate the safety of IMG-007 in adults with Alopecia Areata.
This is a phase 1b/2a, open label study to assess the safety, PK, and efficacy of IMG-007 in adult AA participants with 50% or greater scalp hair loss. The study will consist of two cohorts with three periods: a screening period of up to 5 -weeks, a 16-week treatment period and a 20-week follow- up period. Approximately 6 and 24 participants will be sequentially enrolled into cohort 1 and cohort 2, respectively, to receive three intravenous infusions of IMG-007 over 4 weeks.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
IMG-007 Dose 1 (300 mg) will be administered intravenously 3 times over 4 weeks
Drug: IMG-007
IMG-007 Dose 2 (600 mg) will be administered intravenously 3 times over 4 weeks
Drug: IMG-007
Intravenous Infusion
Evaluation of Adverse Events in Participants
To evaluate adverse events (AEs) emergent from multiple doses of IMG-007 in adult participants with AA.
Time frame: Adverse events were collected from baseline through the end of the study, a period of up to 24 weeks.
Evaluation of Severity of Alopecia Tool (SALT)
To evaluate the efficacy of multiple doses of IMG-007 in AA participants as measured by the Severity of Alopecia Tool (SALT). The Severity of Alopecia Tool (SALT) is a quantitative assessment of AA severity by the investigator based on scalp terminal hair loss. To evaluate the efficacy of multiple doses of IMG-007 in AA participants as measured by Severity of Alopecia Tool (SALT) on a scale of 0 for no hair loss, and 100 is complete hair loss (higher scores attributes to worse outcomes).
Time frame: Mean percent change from baseline in Severity of ALopecia Tool (SALT) at week 24.
| Milestone | IMG-007 300 mg | IMG-007 600 mg |
|---|---|---|
| Started | 6 | 23 |
| Completed | 5 | 23 |
| Not completed | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
To evaluate adverse events (AEs) emergent from multiple doses of IMG-007 in adult participants with AA.
| Participants | IMG-007 300 mg | IMG-007 600 mg |
|---|---|---|
| Participants with at least 1 TEAE | 3 | 19 |
| SAE | 0 | 0 |
| TEAE that was an infusion-related reaction | 1 | 0 |
| TEAE leading to 4-week dosing period discontinuation | 0 | 0 |
| TEAE with outcome of death | 0 | 0 |
To evaluate the efficacy of multiple doses of IMG-007 in AA participants as measured by the Severity of Alopecia Tool (SALT). The Severity of Alopecia Tool (SALT) is a quantitative assessment of AA severity by the investigator based on scalp terminal hair loss. To evaluate the efficacy of multiple doses of IMG-007 in AA participants as measured by Severity of Alopecia Tool (SALT) on a scale of 0 for no hair loss, and 100 is complete hair loss (higher scores attributes to worse outcomes).
| percentage of change | IMG-007 300 mg | IMG-007 600 mg |
|---|---|---|
| Evaluation of Severity of Alopecia Tool (SALT) | -1.07 ± 7.593 | -14.32 ± 3.875 |
Collected over Adverse events were collected from baseline through the end of the study, a period of up to 24 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IMG-007 300 mg | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| IMG-007 600 mg | 0/23 (0%) | 0/23 (0%) | 8/23 (34.8%) |
| Event | IMG-007 300 mg | IMG-007 600 mg |
|---|---|---|
| HeadacheNervous system disorders | 2/6 | 2/23 |
| HypertensionVascular disorders | 0/6 | 2/23 |
| NasopharyngitisInfections and infestations | 0/6 | 2/23 |
| Streptococcal infectionInfections and infestations | 0/6 | 2/23 |
| Age, Categorical(Participants) | IMG-007 300 mg | IMG-007 600 mg | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 6 | 23 | 29 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | IMG-007 300 mg | IMG-007 600 mg | Total |
|---|---|---|---|
| Mean | 42.2 ± 15.51 | 44.7 ± 15.05 | 44.2 ± 14.90 |
| Sex: Female, Male(Participants) | IMG-007 300 mg | IMG-007 600 mg | Total |
|---|---|---|---|
| Female | 6 | 16 | 22 |
| Male | 0 | 7 | 7 |
| Ethnicity (NIH/OMB)(Participants) | IMG-007 300 mg | IMG-007 600 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 2 |
| Not Hispanic or Latino | 6 | 21 | 27 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Severity of ALopecia Tool (SALT) Score(units on a scale) | IMG-007 300 mg | IMG-007 600 mg | Total |
|---|---|---|---|
| Mean | 87.23 ± 15.651 | 78.63 ± 18.401 | 80.41 ± 17.954 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Sep 2023 to primary completion in Jan 2025, 15 months.
Results were first posted in Feb 2026, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: IMG-007
Inmagene LLC